<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722369</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/12/0515</org_study_id>
    <nct_id>NCT02722369</nct_id>
  </id_info>
  <brief_title>STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)</brief_title>
  <official_title>A Phase II, Multicentre, Randomised Trial Comparing Combination Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the combination of gemcitabine/carboplatin with hydroxychloroquine (HCQ)&#xD;
      is associated with an improved clinical outcome (progression free and overall survival)&#xD;
      compared with chemotherapy alone in patients with small cell lung cancer (SCLC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, randomised, phase II trial which aims to compare the combination of&#xD;
      hydroxychloroquine and gemcitabine/carboplatin versus standard carboplatin/etoposide&#xD;
      chemotherapy, as first line treat in patients with stage IV disease.&#xD;
&#xD;
      The standard first line chemotherapy treatment remains a platinum-based chemotherapy and this&#xD;
      has been unchanged for 20 years. Novel active treatment approaches are urgently needed to&#xD;
      improve survival in SCLC.&#xD;
&#xD;
      Patients are randomised to one of two treatment arms; carboplatin/etoposide or&#xD;
      gemcitabine/carboplatin/hydroxychloroquine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment, lack of efficacy and increased adverse events in investigational arm.&#xD;
  </why_stopped>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Defined as the time from randomisation to first progression/death (whichever came first), assessed up to 41 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomisation to death due to any cause, assessed up to 41 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response as measured by Response Evaluation Criteria in Solid Tumours (RECIST) v.1.1</measure>
    <time_frame>From first tumour assessment to progression/trial end (whichever is first), assessed up to 41 months</time_frame>
    <description>Complete Response (CR)/ Partial Response (PR)/ Progressive Disease (PD)/ Stable Disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From date of consent to 30 days after final trial treatment</time_frame>
    <description>Including ophthalmologic and treatment specific toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by EQ-5D</measure>
    <time_frame>From baseline to progression/trial end (whichever is first), assessed up to 41 months</time_frame>
    <description>The questionnaire is a standardised questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by QLQC-30</measure>
    <time_frame>From baseline to progression/trial end (whichever is first), assessed up to 41 months</time_frame>
    <description>The questionnaire is a standardised questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by QLQ-LC-13</measure>
    <time_frame>From baseline to progression/trial end (whicenver is first), assessed up to 41 months</time_frame>
    <description>The questionnaire is a standardised questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance measured by dose intensity</measure>
    <time_frame>From first date of trial treatment to progression/trial end (whichever is first), assessed up to 41 months</time_frame>
    <description>Capturing dose delays, modifications and omissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance measured by dose exposure</measure>
    <time_frame>From first date of trial treatment to progression/trial end (whichever is first), assessed up to 41 months</time_frame>
    <description>Capturing dose delays, modifications and omissions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV carboplatin AUC5 (area under curve) on Day1&#xD;
IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV gemcitabine 1200mg/m2 on Day 1 and Day 8&#xD;
IV carboplatin AUC5 on Day 1&#xD;
Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Investigational Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Investigational Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Maintenance Agent</description>
    <arm_group_label>Investigational Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed SCLC&#xD;
&#xD;
          -  Stage IV disease&#xD;
&#xD;
          -  Performance status ECOG 0-2&#xD;
&#xD;
          -  Life expectancy &gt;8 weeks&#xD;
&#xD;
          -  Age 18 or over&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
          -  Patient considered able to tolerate chemotherapy&#xD;
&#xD;
          -  Adequate renal function - defined by GFR ≥50mL/min as measured by EDTA or C&amp;G&#xD;
&#xD;
          -  Adequate bone marrow reserve: Absolute neutrophil count ≥1.5 x 109/L, haemoglobin ≥90&#xD;
             g/L, platelet count ≥100 x 109/L&#xD;
&#xD;
          -  Negative pregnancy test for WCBP&#xD;
&#xD;
          -  Highly effective contraception is mandatory for all patients of reproductive potential&#xD;
&#xD;
          -  At least one site of measurable disease (target lesion) for RECIST 1.1 evaluation&#xD;
&#xD;
          -  Hypersensitivity or history of severe allergic reaction to any of the IMPs&#xD;
&#xD;
          -  Able to swallow medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed cell histology (i.e. NSCLC and SCLC)&#xD;
&#xD;
          -  Prior macular degeneration or diabetic retinopathy&#xD;
&#xD;
          -  History of glaucoma&#xD;
&#xD;
          -  Patients with abnormal LFTs (ALP, ALT/AST*) that are ≥3 x ULN (≥5 x ULN for patients&#xD;
             with liver metastases)&#xD;
&#xD;
          -  Patients with abnormal bilirubin levels that are ≥1.5 x ULN&#xD;
&#xD;
          -  Prior treatment for this disease e.g. chemotherapy, surgery, radiotherapy (except&#xD;
             palliative radiotherapy to bone metastases)&#xD;
&#xD;
          -  Documented side effects to chloroquine or related agents&#xD;
&#xD;
          -  Treatment with chloroquine or related agents within the last year prior to&#xD;
             randomisation&#xD;
&#xD;
          -  Evidence of significant medical condition or laboratory finding which, in the opinion&#xD;
             of the investigator, makes it undesirable for the patient to participate in the trial&#xD;
&#xD;
          -  Previous medical history of prolonged QT interval&#xD;
&#xD;
          -  A history of prior malignant tumour, unless the patient has been without evidence of&#xD;
             disease for at least 3 years or the tumour was a non-melanoma skin tumour or early&#xD;
             cervical cancer&#xD;
&#xD;
          -  Patients with symptomatic brain metastases&#xD;
&#xD;
          -  Women who are breastfeeding&#xD;
&#xD;
          -  Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs e.g. phenytoin,&#xD;
             carbamazepine, phenobarbital, primidone or oxcarbazepine&#xD;
&#xD;
          -  Patients who are unable to have their digoxin levels regularly monitored&#xD;
&#xD;
               -  if both ALT and AST performed then both need to be recorded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dorset County Hospital NHS Foundation Trust</name>
      <address>
        <city>Dorchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Princess Alexandra Hospital NHS Trust</name>
      <address>
        <city>Harlow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Morecambe Bay NHS Foundation Trust</name>
      <address>
        <city>Lancaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLH</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East and North Herts NHS Foundation Trust</name>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North West Anglia NHS Trust</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Betsi Cadwaladr University Health Board</name>
      <address>
        <city>Rhyl</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Airedale NHS Foundation Trust</name>
      <address>
        <city>Steeton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On receipt of a request the recipient will consider the proposal, ensure relevant Chief Investigator/Trial Management Group are consulted and, if necessary, Trial Steering Committee and/or Cancer Trials Centre (CTC) Senior Management Group. Any shared data will be in an anonymised format</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

